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Microfluidic culture has the potential to revolutionize cancer diagnosis and therapy. Indeed, several micro-
devices are being developed specifically for clinical use to test novel cancer therapeutics. To be effective,
these platforms need to replicate the continuous interactions that exist between tumor cells and non-
tumor cell elements of the tumor microenvironment through direct cell–cell or cell–matrix contact or by
the secretion of signaling factors such as cytokines, chemokines and growth factors. Given the challenges
of personalized or precision cancer therapy, especially with the advent of novel immunotherapies, a critical
need exists for more sophisticated ex vivo diagnostic systems that recapitulate patient-specific tumor biol-
ogy with the potential to predict response to immune-based therapies in real-time. Here, we present de-
tails of a method to screen for the response of patient tumors to immune checkpoint blockade therapy,
first reported in Jenkins et al. Cancer Discovery, 2018, 8, 196–215, with updated evaluation of murine- and
patient-derived organotypic tumor spheroids (MDOTS/PDOTS), including evaluation of the requirement for
3D microfluidic culture in MDOTS, demonstration of immune-checkpoint sensitivity of PDOTS, and ex-
panded evaluation of tumor–immune interactions using RNA-sequencing to infer changes in the tumor–
immune microenvironment. We also examine some potential improvements to current systems and dis-
cuss the challenges in translating such diagnostic assays to the clinic.
Introduction
Monoclonal antibodies targeting immune checkpoints (e.g.
PD-1/PD-L1 axis, CTLA-4) have demonstrated clinical activity
in several malignances (Fig. 1).1,2 Unlike molecular targeted
therapies (e.g. BRAF and EGFR inhibitors), which can be
employed in patients whose tumors harbor select oncogenic
driver mutations (e.g. BRAF V600E, EGFR exon19del or
L858R), to date there are no reliable predictors of response
for immune checkpoint inhibitors. PD-L1 expression predicts
response to anti-PD-1/PD-L1 antibodies in some, but not all
patients, and is increasingly recognized as an imperfect
marker of activity.3 Intense research efforts are now underway
to identify predictive biomarkers of response, toxicity and re-
sistance to immunotherapeutic agents.
There is great interest in studying other immune check-
points and novel combinations of immune modulatory agents
to overcome both innate and acquired resistance to immune
checkpoint blockade (ICB).4,5 Dual ICB with combination PD-
1 and CTLA-4 antibody treatment has recently shown dra-
matic response rates in patients with metastatic melanoma,
however roughly half of patients experienced significant toxic-
ity from the treatment regimen.6,7 Several clinical trials of
combinations of immunotherapeutic agents with molecular
targeted therapies (e.g. kinase inhibitors), cytotoxic chemo-
therapy, and/or radiation are underway, all in the effort to
provide long-lasting disease control to more patients.5 While
the number of these ‘rational’ combination trials continues
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to increase, our understanding of the ‘backbone’ therapy of
PD-1 or CTLA-4 blockade remains far from complete.
Mechanisms of immune escape and resistance to ICB are di-
verse, owing to insufficient numbers of anti-tumor T cells pres-
ent, or ineffective immune response due to local (e.g. tumor or
stromal derived) factors that impair the cytotoxic immune
response.8–11 Approaches to identify cellular, pathologic, im-
munologic, or molecular features that distinguish responding
from non-responding patients have evaluated local features in
the tumor microenvironment using immunohistochemical or
transcriptomic evaluation of frozen or fixed tissue from bio-
psies, and circulating levels of select immune cells or cyto-
kines.12,13 As biopsies from patients who have responded to
ICB often demonstrate the presence of an inflammatory infil-
trate within the tumor, and gene expression profiling studies
have confirmed upregulation of pro-inflammatory cytokines
and chemokines within tumors following PD-1 blockade, there
is increasing interest in understanding the role of the tumor
microenvironment in the response to ICB.12,13 Development of
more sophisticated pre-clinical and ex vivo cancer models that
recapitulate human tumor biology may facilitate efforts to pre-
dict response to targeted and immune-based therapies.
There is growing interest in capitalizing on the increasing
availability of 3D culture systems to tackle important ques-
tions in cancer biology, especially with the recent integration
of microfluidic systems. 3D-microfluidic culture systems now
offer a greater level of precision for evaluating a host of com-
plex biological phenomena in relevant model systems.14 With
the advent of ICB and the expanding number of novel immu-
notherapies and combination therapies, there is increasing
interest in the use of 3D culture systems to interrogate the tu-
mor immune microenvironment.15
Recently, we described a novel method of profiling re-
sponse to PD-1 blockade using organotypic tumor spheroids
cultured in collagen hydrogels suspended in a 3D micro-
fluidic device.5 Patient- or murine-derived organotypic tumor
spheroids (MDOTS/PDOTS) retain autologous immune cells
and respond to PD-1 blockade ex vivo.16,17 Using murine tu-
mors from established PD-1 responsive or resistant tumors,
we were able to recapitulate sensitivity and resistance to ICB
ex vivo. MDOTS/PDOTS also served as a platform to test novel
combination therapies in combination with PD-1 blockade,
including inhibitors or TBK1 (ref. 17) and CDK4/6,17 both of
which enhanced response to PD-1 blockade ex vivo and sub-
sequently in vivo efficacy was confirmed. In this paper, we
will describe in detail the methods of MDOTS/PDOTS plat-
form (“version 1.0”), and propose some novel applications
and future directions.
Materials and methods
Patient samples
Tumor samples were collected and analyzed according to
Dana-Farber/Harvard Cancer Center IRB-approved protocols.
Informed consent was obtained from all patients. These stud-
ies were conducted according to the Declaration of Helsinki
and approved by the MGH and DFCI IRBs.
Syngeneic murine models
All animal experiments were performed in compliance with
established ethical regulations and were approved by the
Dana-Farber Animal Care and Use Committee. MC38 murine
colon adenocarcinoma cells were generously provided by Dr.
Gordon Freeman (DFCI) received under an MTA from Dr. Jef-
frey Schlom of NCI (Bethesda, MD). CT26 colon carcinoma
cells were purchased from ATCC (2015). Mouse tumor im-
plantations were performed as previously described.17
Device design and fabrication
MDOTS and PDOTS were evaluated using ‘3-D cell culture
chip’ (DAX-1, AIM BIOTECH, https://www.aimbiotech.com/),
as previously described.16,18 Microfluidic device design and
fabrication using cyclic olefin polymer (COP) conducted at
AIM BIOTECH. Briefly, the single layer slide format (75 mm ×
25 mm) device or ‘chip’, consists of 3 microfluidic chambers
each with a central gel channel (width 1.3 mm) flanked by
two media channels (width 0.5 mm). The height of the micro-
fluidic chambers is 0.25 mm. Media channels were designed
including larger reservoirs to prevent over-aspiration
(Fig. 3A–C).
Preparation of MDOTS/PDOTS and ex vivo microfluidic 3D
culture
MDOTS/PDOTS (S2 fraction; 40–100 μm) containing tumor, im-
mune, and stromal cells were prepared as described previ-
ously.17 Briefly, fresh tumor specimens (murine and human pa-
tients) were received in media (DMEM or RPMI) on ice and
Fig. 1 Schematic of PD-1/CTLA-4 blockade. Schematic detailing basic
steps involved in generation of tumor-specific T cells. Shown is a sche-
matic of a tumor cell, CD8 effector T cell, and an antigen-presenting
cell (APC), with associated cell–cell interactions via PD-1/PD-L1 and
CTLA-4/B7. Tumor-associated antigens or neo-antigens are presented
by major histocompatibility complex (MHC) on APCs or tumor cells to
T cells with appropriate T-cell receptor (TCR). CD28 co-activating re-
ceptor on T cells binds B7 on APCs. Anti-PD-(L)1 and anti-CTLA-4 anti-
bodies are shown.
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minced in a standard 10 cm dish using sterile forceps and scal-
pel. Minced tumor was resuspended in high-glucose DMEM (or
RPMI, for CT26) with 100 U mL−1 type IV collagenase, and 15
mM HEPES (Life Technologies, Carlsbad, CA). Samples were in-
cubated at 37 °C and evaluated every 15 minutes to monitor for
adequate formation of spheroids with modest release of single
cells. Following digestion (range: 15–60 min), equal volumes of
media were added to minced tumor specimens and samples
were pelleted and resuspended in fresh media and passed over
100 μm and 40 μm filters sequentially to obtain S1 (>100 μm),
S2 (40–100 μm), and S3 (<40 μm) spheroid fractions, which
were subsequently transferred to ultra low-attachment tissue
culture plates. An aliquot of the S2 fraction was pelleted and
resuspended in type I rat tail collagen and the spheroid–colla-
gen mixture was injected into the center gel region of the 3D
microfluidic chamber (10 μL per each microfluidic chamber).
After incubation for 30 minutes at 37 °C in sterile humidity
chambers, collagen hydrogels containing PDOTS/MDOTS were
hydrated with media with or without indicated therapeutic
monoclonal antibodies – MDOTS: isotype control IgG (10 μg
Fig. 2 MDOTS/PDOTS workflow. (A and B), A tumor specimen is received and subjected to physical and enzymatic dissociation (A), yielding
dissociated tumor tissue (B) containing spheroids, single cells, and macroscopic tumor. (C and D), This heterogeneous mixture is then sequentially
applied to 100 μm and 40 μm filters (C) to obtain three separate fractions (D), S1 (>100 μm), S2 (40–100 μm), and S3 (<40 μm). E, The S2 fraction
is pelleted and resuspended in collagen to be injected into the microfluidic culture device for subsequent ex vivo culture with indicated terminal
readouts. Scale bars indicate 100 μm (D and E).
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mL−1, clone 2A3) or anti-PD-1 (10 μg mL−1, clone RMP1-14);
PDOTS: anti-PD-1 (pembrolizumab, 250 μg mL−1), anti-CTLA-4
(ipilimumab, 50 μg mL−1), or combination (250 μg mL−1
pembrolizumab + 50 μg mL−1 ipilimumab), as previously
shown.17
Live/Dead and immunofluorescence staining of MDOTS/
PDOTS
Live/Dead fluorescence staining was performed using AO/PI
staining solution, as previously described.17 Following incu-
bation with AO/PI or Hoechst/PI (20 min, room temp,
protected from light) or Hoechst/PI (45 min, 37 °C, 5% CO2),
images were obtained. Image capture and analysis were
performed using a Nikon Eclipse 80i fluorescence microscope
equipped with Z-stack (Prior), motorized stage (ProScan) and
ZYLA5.5 sCMOS camera (Andor) and NIS-Elements AR soft-
ware package. Live and dead cell quantitation was performed
by measuring total cell area of each dye. For direct immuno-
fluorescence staining coupled with Live/Dead analysis,
unfixed live MDOTS or PDOTS were washed with PBS and
blocked with Fc receptor (FcR) blocking reagent (PDOTS,
Miltenyi; MDOTS, BioLegend) for 30 minutes at room tem-
perature. Directly conjugated antibodies for PDOTS were
CD326 EpCAM-PE (clone 9C4), CD45-AlexaFluor-488 (HI30),
CD8a-AlexaFluor488 (RPA-T8); for MDOTS, CD45-
AlexaFluor488 or 647 (30-F11), CD8α-PE (53-6.7; BioLegend).
Antibodies were diluted 1 : 50 in 10 μg mL−1 solution of
Hoechst 33342 (in PBS) and loaded into microfluidic cham-
bers for 1 hour incubation at room temperature in the dark.
Spheroids were washed twice with PBS with 0.1% Tween20
followed by PBS. For viability assessment, microfluidic cham-
bers were loaded with 1 : 1000 solution of calcein AM in PBS.
Live/Dead analysis in 2D conditions
S2 fraction of CT26 tumors was split and seeded in 3-D cell
culture chips parallel with flat bottom CellBind surface 384-
well plate (Corning, #3683). 2D experiment was performed as
following: spheroids were loaded in wells of 384-well plate in
triplicates in 2 densities of ∼15 and ∼30 spheroids/well in
cultural media containing either IgG or αPD-1 at 10 μg mL−1.
Plate was incubated in humidity chamber at 37 °C, 5% CO2
for 5 days. At the end media was gently removed and 20 μL
of AOPI (Nexcelom) was loaded into each well. After 20 min-
ute incubation in the dark at RT cells were imaged on
inverted Nikon Eclipse Ti microscope equipped with Nikon
DS-Qi1Mc camera using NIS-Elements software. Total area of
AO-stained live cells versus propidium iodide-stained dead
cells was quantified. CT26 tumor spheroids seeded in both
high and low densities produced similar results, graph for
the high density is shown.
Cytokine profiling
Media collected from MDOTS/PDOTS culture at the indicated
time point were removed (by micropipette) and transferred to
1.5 mL Eppendorf tubes. After collection, tubes containing
conditioned media were placed on dry ice before storage at
−80 °C. For bead-based cytokine profiling, conditioned media
were thawed on ice. Four panels of multiplex ELISA assays
were performed utilizing a bead-based immunoassay ap-
proach, the Thermo Fisher Immuno-Oncology Checkpoint 14-
plex Human ProcartaPlex™ panel 1 (Cat No. EPX14A-15803-
901), Bio-Rad Bio-Plex Pro Human Cytokine 27-plex panel
(Cat No. m500kcaf0y), and Human Inflammation 37-plex
panel (Cat No. 171AL001M), and Human Cytokine 40-plex
panel (Cat No. 171AK99MR2). MDOTS/PDOTS conditioned
media concentration levels (pg mL−1) of each protein were de-
rived from 5-parameter curve fitting models, and fold
changes (relative to untreated or IgG control) were calculated
and plotted as log2FC. Lower and upper limits of quantita-
tion (LLOQ/ULOQ) were imputed from standard curves for cy-
tokines above or below detection. Conditioned media from
PDOTS were assayed neat. Only detectable cytokines were in-
cluded in the analysis.
Fig. 3 Microfluidic device. (A), The 3D cell culture chip (AIM Biotech)
is shown with three independent microfluidic chambers per chip. Red
rectangle identifies a single microfluidic chamber in the 3D cell culture
chip. (B and C), Each device contains a center gel region with posts
separating the gel region from the anti-parallel side channels. Gel
loading port and media ports labeled (B), along with center and side
channels (C).
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RNA-sequencing (RNA-seq) and CIBERSORT
RNA-seq was performed as previously described.1 For RNA-
seq studies, SI-NET PDOTS were cultured in 3D cell culture
chips (AIM BIOTECH). In brief, RNA lysates were prepared
from SI-NET PDOTS on day 9 using the lysis buffer from
Agencourt RNAdvance kit (using 1 : 20 proteinase K). Condi-
tioned media was removed (as described above), before 200
mL of lysis buffer (with proteinase K) was added to each
microfluidic chamber. Devices were incubated for 25 min at
37 °C, lysates were collected from each microfluidic chamber,
and were transferred to RNase-free microcentrifuge tubes,
and then stored at −80 °C. RNA were extracted using
RNAdvance Tissue kit (Beckman Coulter, Cat. No. A32649).
RNA quantity and quality were assessed using Quant-iT™
RiboGreen™ RNA Assay Kit (Thermo Fisher, Cat. No.
R11490) and Agilent Bioanalyzer RNA 6000 pico kit (Agilent,
Cat. No. 5067-1513). RNA libraries were prepared from 10 ng
RNA per sample using Illumina Truseq RNA Access protocol
(Illumina, Cat No. RS-301-2001). RNA-seq was performed at
the DFCI Molecular Biology Core Facilities (Illumina NextSeq
500). RNA-seq data were aligned and differential expression
analysis were performed using VIPER pipeline, as de-
scribed.19 CIBERSORT was performed as described20 (https://
cibersort.stanford.edu).
Results & discussion
Sample preparation: basic principles and practical experience
To recapitulate the biology of the tumor immune microenvi-
ronment to model PD-1 blockade, one needs viable tumor tis-
sue, autologous tumor-infiltrating immune cells, and an ap-
propriate device and model extracellular matrix to permit
3-dimensional culture. When devising the workflow for
PDOTS/MDOTS processing, we aimed for simplicity. As some
immune cells lose viability within hours of collection, we felt
it was essential to minimize the time required for tumor
specimen processing. At the same time, we avoided added
growth factors or cytokines to selectively support the viability
or growth of lymphoid or myeloid cells as this might artifi-
cially alter biological response to ICB. Therefore, we used tra-
ditional cell culture media (DMEM or RPMI) supplemented
with 10% FBS. In our initial pilot studies, this standard cul-
ture medium supported the growth of both MDOTS and
PDOTS so further modification was not necessary.
Generation of MDOTS/PDOTS requires fresh tumor speci-
mens from immune competent mouse models or patients.
Several syngeneic murine cancer models have been profiled,
including MC38 colon, CT26 colon, B16 melanoma, Lewis
lung carcinoma, and GL261 glioblastoma. Diverse solid tu-
mor types have been profiled to date, including primary le-
sions, lymphadenectomy specimens, pleural effusions, ascites
fluid, and resected metastases. Baseline viability and sample
size is essential for immune cell profiling and ex vivo culture.
Surgical (excisional) specimens are ideal for PDOTS prepara-
tion, and are similar to the explanted murine tumors used
for MDOTS preparation (Fig. 2A).
While bacterial contamination was rare, all experiments
were performed with antibiotics (1% penicillin–streptomycin).
For primary colorectal cancer specimens (exposed to the gas-
trointestinal lumen and commensal bacteria), addition of
metronidazole and gentamicin was required for Gram nega-
tive and anaerobic bacteria. For oropharyngeal head and
neck squamous cell carcinomas, anti-fungal coverage (e.g.
amphotericin B) was required to prevent contamination with
Candida. Bacterial or fungal contamination was not encoun-
tered for cutaneous metastases, as the skin was sterilized
prior to obtaining the excisional biopsy.
There is no minimum size cutoff, but rather sample qual-
ity, cellular viability, and immune cell composition are more
important characteristics. For example, fine needle aspirates
(FNAs) and core needle biopsies often yield far fewer cells
than surgical (excisional) biopsies, and in our hands viability
is frequently poorer from needle biopsies. On the rare occa-
sion in which core needle biopsy yields viable cells and
spheroids, there is often an insufficient number of PDOTS
for extensive ex vivo profiling, thereby limiting the number of
experimental conditions and replicates that are possible. On
the other hand, pleural effusions and ascitic (peritoneal)
fluid usually in cancer patients often generate at least 0.5–1
liter of fluid, and for most adenocarcinomas (e.g. lung, thy-
roid, breast) tumor cells are already aggregated with immune
cells in multicellular spheroids.
With the exception of pleural effusions and peritoneal
fluid (ascites) specimens, the initial step in processing in-
volves physical and enzymatic dissociation using a limited
collagenase digestion (see Materials and methods). Type IV
collagenase is used in this step as it has low tryptic activity,
and it was used at a dilute concentration to avoid complete
dissociation of MDOTS or PDOTS to single cells. The amount
of time required to digest minced tumor tissue with type IV
collagenase (in media) varies from sample to sample, and tu-
mor to tumor. In general more fibrous tumors (e.g. mesothe-
lioma) require longer incubation times (up to 30–60 min),
compared to most samples (20–30 min). Some murine tumor
explants require only very brief collagenase treatment, as lon-
ger incubations have yielded an excess of single cells relative
to spheroids.
Following physical and enzymatic dissociation, the
minced and digested tumor specimen contains a mixture of
macroscopic undigested tissue, spheroids, and single cells
(Fig. 2B). Spheroids are isolated following passage of the dis-
sociated specimen over a series of filters (100 μm and 40 μm)
(Fig. 2C and D).
The second fraction (S2; 40–100 μm) is subsequently used
for MDOTS/PDOTS profiling and ex vivo culture (Fig. 2E). S1
and S3 fractions can be frozen or banked, or used for im-
mune cell profiling.
3D microfluidic culture
The majority of our studies to date utilized the commercially
available DAX-1 3-D cell culture chip (AIM Biotech). Three
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self-contained microfluidic chambers are present on a single
‘3D cell culture chip’ (Fig. 3A). Following preparation of the
S2 fraction, MDOTS/PDOTS are pelleted briefly and
resuspended in a neutral pH collagen solution (see Materials
and methods). The collagen solution is prepared fresh for
each experiment and is always prepared in excess. Pelleted
MDOTS or PDOTS are initially re-suspended in a smaller vol-
ume of collagen (e.g. 100–200 μL) based on the size of the
pellet, and then 10 μL is loaded into a single microfluidic
chamber to confirm spheroid density and/or used for auto-
mated cell counting. Methods to accurately quantify the num-
ber of cells per spheroid (or cells per microfluidic chamber)
are limited, but we will adjust the volume of collagen with a
given number of spheroids to obtain approximately 10–20 000
cells per microfluidic chamber (based on automated cell
counting technologies).
The collagen–spheroid mixture is kept on ice and injected
into the upper and lower gel loading ports, such that the col-
lagen–spheroid mixture extends almost half way to the oppo-
site gel loading port, before the pipet tip is transferred to the
opposite (lower) gel loading port to inject the remaining
spheroids, such that the two pools of spheroids ‘meet’ in the
middle of the gel region (Fig. 3A–C). After all microfluidic
chambers are loaded in a similar fashion, they are trans-
ferred from the tissue culture hood into sterile humidity
chambers and placed in a sterile incubator (37 °C) for 30
min. During this incubation, the culture media is prepared
with the various antibody or drug treatments. After the 30
min incubation is complete, each microfluidic chamber is hy-
drated with 250–300 μL of media (depending on the down-
stream application and frequency of media changes)
containing the desired final concentration of the drug or
antibody of interest. The chambers are then returned to the
incubator in the aforementioned humidity chamber and can
be cultured from 5–9 days (5–6 days routinely, especially for
MDOTS which grow quickly).
MDOTS/PDOTS readouts
In the initial publication describing MDOTS/PDOTS method-
ology (Jenkins et al.),17 we featured five different methods of
analysis of MDOTS/PDOTS: light/phase contrast microscopy,
time-lapse (live) imaging, immunofluorescence microscopy,
Live/Dead imaging, and secreted cytokine profiling. Much of
the routine analysis of ex vivo response to PD-1 blockade fo-
cused on dynamic secreted cytokine changes using bead-
based cytokine profiling and fluorescence imaging using via-
bility dyes for quantitative live/dead assessment.
Evaluation of immune-mediated tumor cell killing by ef-
fector CD8 T cells is central to the evaluation of ex vivo profil-
ing of PD-1 blockade. In our initial publication,16 and com-
panion study featuring PDOTS/MDOTS,17 dual labeling
fluorescence dyes for both qualitative and quantitative Live/
Dead imaging was performed with acridine orange (AO) and
propidium iodide (PI). AO/PI labeling for Live/Stain fluores-
cence Live/Dead staining has been in use for several decades,
and are commercially available, inexpensive, and easy-to-use.
PI is a cell impermeable DNA dye that only stains cells follow-
ing membrane damage (e.g. necrosis or late apoptosis) after
which it binds nuclear DNA. AO is a membrane-permeable
nucleic acid-binding dye. Therefore, live nucleated cells emit
green fluorescent signal (AO permeable, PI excluded),
whereas dead cells become permeable to PI, and pure red
fluorescence is evident in dead cells due to quenching of
green fluorescence by PI due to Forster (fluorescence) reso-
nance energy transfer (FRET). Shown are MC38 MDOTS
treated with isotype control IgG antibody or anti-PD-1 anti-
body (Fig. 4A) where treatment with the anti-PD-1 antibody
results in CD8 T-cell-mediated tumor cell killing, as previ-
ously demonstrated.17 Modifications to this protocol have
been used with Hoechst 33342 (Ho) as a viability dye, instead
of AO (Fig. 4B). Ho/PI staining can be a useful alternative for
viability staining of cells with large cell size, high cytoplasm :
nucleus ratio, and/or multiple cellular projections (e.g. CT26
murine colon carcinoma cells), to make threshold-setting
more feasible. Quantification of Ho/PI and AO/PI fluores-
cence, as shown for CT26 MDOTS, demonstrates that sensi-
tivity to PD-1 blockade is maintained in 3D microfluidic cul-
ture, but cannot be detected using MDOTS in 2D culture
using 384-well plates (Fig. 4C and D).
In addition to use of fluorescent dyes, direct immunofluo-
rescence labeling can also readily be performed using
MDOTS and PDOTS.16,17 Standard immunofluorescence la-
beling protocols, coupled with viability dye evaluation using
calcein AM (Fig. 5A–C), can also be employed to evaluate via-
bility of different cell types. Calcein AM is cleaved to its fluo-
rescent form by intracellular non-specific esterases, and in
combination with Hoechst can be used to quantify cellular vi-
ability. Direct immunofluorescence using cell surface pro-
teins to delineate tumor cells and immune cells is of great
utility, especially in PDOTS specimens that demonstrate great
inter-sample variability (Fig. 5A–C). Shown here are PDOTS
from high-grade serous carcinoma (HGSC) of the ovary and
non-small cell lung carcinoma (NSCLC), where tumor cells
are readily detected using EpCAM antibodies. Staining for
CD8 readily identifies effector CD8 + T cells present in
PDOTS, which are necessary effectors following treatment
with anti-PD-(L)1 antibodies.12 To date, we have focused on
using direct immunofluorescence (IF) coupled with viability
dyes in live, intact cells although multiplexed IF is under in-
vestigation. For example, PDOTS from patients with mela-
noma do not express EpCAM, and most reliable melanoma
markers are intracellular proteins, which cannot be readily vi-
sualized in live, unpermeabilized cells. More sophisticated
imaging, including evaluation of intracellular markers re-
quires fixation and permeabilization, which precludes use of
non-fixable viability dyes. Ideal panels would permit detec-
tion of tumor cells and immune cells (lymphoid and mye-
loid), expression of PD-1 and PD-L1, as well as viability in dis-
tinct cellular subsets.
Secreted cytokine profiling using multiplexed bead-based
kits permits analysis of a large number of inflammatory
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cytokines and chemokines from a small volume of condi-
tioned media, serum, or plasma. In profiling PDOTS or
MDOTS, conditioned media is collected at indicated time
points, or upon termination of ex vivo culture, and frozen
(at −80 °C), banked, and later batched for pooled analysis
using either murine or human commercially available cyto-
kine kits. For a given sample, routine Live/Dead analysis
(Fig. 6A) can be formed after media collection and banking
for bead-based cytokine profiling (Fig. 6B). In the PDOTS
sample shown from a patient with a small intestinal neuro-
endocrine tumor (SI-NET), dual immune checkpoint block-
ade with αPD-1 + αCTLA-4 enhanced immune-mediated
Fig. 4 Live/Dead imaging and analysis of murine-derived organotypic tumor spheroids. (A), Acridine orange (AO) and propidium iodide (PI) staining
of MC38 MDOTS on day 6 of ex vivo culture, comparing control (isotype control IgG, 10 μg mL−1) with anti-PD-1 (10 μg mL−1). B, AO/PI and
Hoechst/PI staining of CT26 MDOTS on day 5 of ex vivo culture, comparing control (isotype control IgG, 10 μg mL−1) with anti-PD-1 (10 μg mL−1).
C and D, Live/Dead analysis (C) and fluorescence images (D) of CT26 MDOTS treated with IgG or anti-PD-1 (10 μg mL−1) for 5 days in 3D micro-
fluidic culture (“3D”) compared to 384-well plates (“2D”) (3D – Ho/PI; 2D – AO/PI) (****p < 0.0001, ns = not significant; Kruskal–Wallis with multi-
ple comparisons; n ≥ 3). Scale bars indicate 200 μm (A, B and D).
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killing compared to single-agent PD-1 blockade and CTLA-4
blockade (Fig. 6A). For the PDOTS specimen featured
(Fig. 6B), the evolution of cytokine and growth factor secre-
tion is evident over time (days 1, 3, 6, and 9), with the
clearest differences between the treatment groups evident
by day 9 (e.g. IL-8, VEGF, Il-12 (p70), CCL4). A single PDOTS
(or MDOTS) sample yields >200 μL of media, enough for
four separate bead-based profiling runs (each requiring 50
μL of conditioned media).
Despite the ease of using bead-based profiling to evalu-
ate secreted cytokines and growth factors from condi-
tioned media, most panels are not exhaustive and running
multiple panels on individual samples is impractical and
costly. Furthermore, for discovery efforts and pathway
analysis, secretion profiling is unlikely to evaluate a suffi-
cient number of effectors, growth factors, and
chemoattractants. Lastly, molecular analysis (e.g. RNA-seq)
provides a large data set that can be interrogated to infer
changes in immune cell populations (e.g. CIBERSORT20).
We performed a pilot study to determine if bulk RNA-
sequencing (RNA-seq) could be performed on PDOTS and
conducted CIBERSORT analysis to determine if ex vivo
treatment with αPD-1 +/− αCTLA-4 influenced relative
number of immune cells (inferred by RNA-seq). RNA was
purified using a modified lysis protocol utilizing protein-
ase K to digest collagen gels and cellular membranes,
Fig. 5 Fluorescence imaging of patient-derived organotypic tumor spheroids. (A and B), Baseline IF staining of HGSC PDOTS demonstrating viable
cells (calcein AM; green), CD8 T cells (red), tumor cells (EpCAM; purple), and all nucleated cells (Hoechst; blue). C, Overlay IF image of NSCLC
PDOTS demonstrating EpCAM positive tumor cells (green), all nucleated cells (Hoechst; blue), and dead cells (PI; red). Scale bars indicate 20 μm
(A–C).
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total RNA from the mixed cell population was isolated
(see Materials and methods), and was used as input for li-
brary prep for RNA-seq. CIBERSORT was performed (as de-
scribed20), and demonstrated relative expansion of CD8 T
cells and M0 macrophages in PDOTS treated with dual
ICB (αPD-1 + αCTLA-4) relative to control or single agent
ICB-treated PDOTS. While this is an initial proof of con-
cept experiment, it suggests that RNA-seq from PDOTS in
3D microfluidic culture is feasible, and that CIBERSORT
or similar computational methods can be used to infer
immune cell changes in response to ex vivo ICB.
Discussion
We have previously demonstrated that patient- and murine-
derived organotypic tumor spheroids retain relevant lym-
phoid and myeloid subsets of immune cells, grow readily in
3D microfluidic culture in collagen hydrogels, recapitulate
sensitivity and resistance to PD-1 blockade ex vivo using
established immune competent murine tumor models, to
test novel combination therapies using a PD-(L)1 backbone,
and demonstrated the utility of PDOTS profiling to identify
and nominate candidate biomarkers.17 Here, we review this
Fig. 6 Ex vivo profiling of ICB using PDOTS. (A), AO/PI staining of SI-NET PDOTS (day 9) treated with αPD-1, αCTLA-4, and αPD-1 + αCTLA-4
compared to untreated control PDOTS. (B), Heatmap of changes in secreted cytokines from PDOTS (SI-NET); represented as L2FC relative to
untreated control at each time point. (C), Inferred changes in PDOTS immune cell populations using CIBERSORT from SI-NET PDOTS RNA-seq.
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Table 1 Summary of the advantages/limitations of MDOTS/PDOTS microfluidic culture models relative to other in vivo and in vitro cancer models. Sev-
eral typical references are provided for each type of culture
Type
culture Cancer models Characteristics/advantages Limitations
In vitro
ex vivo
3D microfluidic
culture of:26–32
Culture
conditions
• Ideal to study immune–tumor
interaction in 3D microenvironment
Culture
limitations
• Inability to recapitulate biological in vivo
interactions within the entire animal
(except for body on a chip platforms)
• Capable of modeling complex tumor
microenvironment (TME) and
extra-cellular matrix (ECM)
• Variability in number of spheroids
within the device
• Use of patient-derived and mouse
specimens (PDOTS, MDOTS) or cell
lines (cell line spheroids)
• Difficult to maintain long-term culture
(months)
• Dynamic multicellular co-culture • Difficult to provide correct cell culture
medium
• Reproduces paracrine and contact
interactions
• Risk of contamination during
handling
• Accounts for 3-dimensional cancer
cell growth
• Mimics local in vivo organization
• Medium-term culture
(1–2 weeks)
Cell line
spheroids18,29,30,32
Material &
methods
• Requires low number of cells Technical
issues
• Low reproducibility and variability
in data (PDOTS)• Ability to modulate cytokine/gradients
• Reduces reagents
MDOTS16,17 • Possibility to include fluid flow
stimuli with pumps
• Inability to reproduce same experiments
(PDOTS) unless after “Bio-banking”
of sample and create cell lines from patient
• Microfluidic devices are scalable
(size, number of cells)
• Difficult to evaluate/extract results
PDOTS16,17 Results &
potentiality
• Reproducible experiments (cell
line, MDOTS)
• Requires cell sorting to collect protein
lysate and RNA from each cell populations
• Imaging in real-time • Requires experienced operatorĲs) and
training
• Capable of evaluating drug toxicity
and drug metabolism
• Low throughput screening (potential
medium to high throughput screening)
• Live/Dead assays • High cost (MDOTS, PDOTS)
• Cytokine profiling
• High reproducibility with same mouse
background (MDOTS)
• Can be applied for migration studies
(immune cells)
• Ease of bulk protein RNA collections
• Low cost (cell line spheroids)
• Potential for personalized medicine
In vitro
ex vivo
2D standard cell
culture31–35
Culture
conditions
• Ideal to study single cancer cell
autonomous processes
Culture
limitations
• Inability to recapitulate biological in vivo
interaction within entire human body
• Use of patient-derived and commercial
cell line
• Static 2-dimensional culture
• Simple technical culture • Lack of the TME
• Reproducible experiments • Fails to account for 3-dimensional
cancer cell growth
• Low-, medium- to long-term culture • Lack ECM
Material &
methods
• Require cells, cell culture medium and
culture dishes
• Lack immune cells
• Potential genetic changes of cancer
cells over time
• No multicellular co-culture
• No possibility to include fluid flow
stimuli with pumps
• Low-throughput screening
Results &
potentiality
• Potential change of the genetic
background of original cancer cells
Technical
issues
• Live/Dead assay
• Cytokine profiling
• Imaging in real-time
• Easy methods to collect protein
lysates and RNAs
• Easy evaluate/extract results capable
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Table 1 (continued)
Type
culture Cancer models Characteristics/advantages Limitations
of evaluating drug toxicity and drug
metabolism
• Low costs
• High-throughput screening
(up to 96- or 384 well plates)
In vitro
ex vivo
Standard transwell
culture36–40
Culture
conditions
• Ideal to study paracrine signaling,
chemotaxis (immune cells) and
vascular permeability (drugs)
Culture
limitations
• Inability to recapitulate biological in vivo
interaction
• Modulate cytokine/gradients • Do not mimic contact interactions in the
TME
• Simple technical culture • Low mimic of in vivo organization
• Dynamic multicellular co-culture
• 2D coating with ECM
• Medium- to long-term culture
Material &
methods
• Require cells, cell culture medium,
transwell insert (membrane) and
culture wells
Technical
issues
• Gravity force (g) may affect results
• Possible apply trans-endothelial flow
with custom made/commercial platforms
• Difficult imaging
(depends on membrane transparency)
Results &
potentiality
• Capable of evaluating drug toxicity
and drug metabolism
• Cytokine profiling
• Easy collect protein lysate and RNA
from each cell population without sorting
• Easy/reproducible results
• Low costs
• High-throughput screening
(up to 96- or 384 well plates)
In vitro
in vivo
ex vivo
Circulating tumor
cells (CTCs)24,41–46
Culture
conditions
• Not invasive methods of isolation from
blood
Culture
limitations
• Difficult to provide protocols/medium
for culture
• Multicellular co-culture • Lacks native immune and stromal cells
• Medium-term culture
(1–2 weeks)
• Possible different biology
between circulating tumor cells and
tumor within native microenvironment• Versatile and compatible with multiple
platforms and type of culture (3D culture,
organoids, in vivo mouse models)
Material &
methods
• Use of patient-derived specimens Technical
issues
• Often present only in patients with
large disease burden
• Takes time to propagate sufficient
material for drug screening/testing
Results &
potentiality
• Potential for personalized medicine • Difficult evaluate/extract results
• Imaging in real-time • Medium- to high costs
• Following propagation, CTCs can be
used for anti-neoplastic drug testing
• Low to medium throughput screening
In vitro
ex vivo
Organoids21,22,47–49 Culture
conditions
• Ideal to recapitulate the
pathophysiology of the original tumor
Culture
limitations
• Lacks native immune and stromal
elements
• Model complex tumor
microenvironment TME
• Takes time to propagate sufficient
material for drug screening/testing
• Single/multicellular co-culture • Difficult to provide correct protocols/
cell culture medium
• Account for 3-dimensional cancer
cell growth
• Risk of contamination for high handling
level
• Mimic in vivo organization
• Multiple methods of isolation from
peripheral blood
• Amenable to repeat evaluation
(“living biobank”)
• Medium- to long-term culture
(up to months)
Material &
methods
• Use of patient-derived specimens
or cell lines
Technical
issues
• Difficult to evaluate/extract results
• Require cell sorting to collect protein
lysate and RNA from each cell populations
(multi-cellular organoids)
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previously published method in greater detail with emphasis
on the methods of MDOTS/PDOTS preparation and readouts,
and discuss future directions with this novel technology (e.g.
RNA-seq), and provide further evidence 3D microfluidic cul-
ture of MDOTS recapitulates response to PD-1 blockade which
is lacking using traditional 2D culture methods.
The PDOTS/MDOTS platform offers several advantages
over existing methods to evaluate tumor–immune responses
Table 1 (continued)
Type
culture Cancer models Characteristics/advantages Limitations
Results &
potentiality
• Imaging in real-time • Low to medium throughput screening
• Capable of evaluating drug toxicity and
drug metabolism
• Easy – bulk protein lysates and RNA
extractions
• Low to medium costs
• Potential for personalized medicine
In vivo Xenografts mouse
models23,31,33,50–54
Culture
conditions
• Ideal to study biological in vivo
interaction within the entire animal
body in vivo culture system using
patient-derived specimens
Culture
limitations
• Time and labor-intensive
• Account for 3-dimensional cancer cell
growth
• Challenging imaging in real-time
• Mimic in vivo organization and TME • Requires experienced operatorĲs)
and training
• Multicellular co-culture • Genetic differences between species
• Long-term culture (over months) • Complex infrastructure and
specific technical skills required
• Incompatible with high-throughput
screening
• Lack of immune cells
• Fluid flow stimuli by in vivo circulation
Material &
methods
• Require mouse and animal facility Technical
issues
• Require long culture to quantify results
• Challenging variability in data
Results &
potentiality
• Patient derived xenograft (PDXs) derived
from mouse models can be cultured in 3D
microfluidic device or grown as organoids
• Collect protein lysate and RNA
after sacrifice mouse
• High costs
• Low throughput screening
In vivo Immune-competent
mouse
models31,33,54–56
Culture
conditions
• In vivo culture system using
patient-derived specimens
Culture
limitations
• Time and labor-intensive
• Biological in vivo interaction
within the entire animal body
• Challenging imaging in real-time
• Include immune interactions • Requires experienced operatorĲs)
and training
• Account for 3-dimensional cancer
cell growth
• Complex infrastructure and
specific technical skills required
• Mimic in vivo organization and TME • Limited number of potential drug
combinations
• Long-term culture (over months) • Drugs and therapeutic antibodies
against mouse targets may differ
from human targets
• Only mouse cells study
Material &
methods
• Require mouse and animal facility Technical
issues
• Require long culture to quantify
results
Results &
potentiality
• Capable of modeling heterogeneity
of in vivo response and resistance
• Capable of evaluating drug toxicity
and drug metabolism
• Challenging variability in data
• Fluid flow stimuli by in vivo circulation • Collect protein lysate and RNA after
sacrifice mouse
• Useful for evaluating drugs whose
mechanism of action takes time (e.g.
epigenetic modifying agents)
• High costs
• MDOTS derived from
immune-competent mouse models can be
cultured in 3D microfluidic device or
grown as organoids
• Low throughput screening
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to ICB (see Table 1), providing a window into the tumor im-
mune microenvironment and enabling evaluation of acute
and dynamic responses to ICB to using relevant murine
models and patient samples. Unlike organoids,21,22 patient-
derived xenografts (PDXs),23 and circulating-tumor cells
(CTCs),24 MDOTS and PDOTS do not require days or weeks of
tissue manipulation or propagation, and contain autologous,
tumor-infiltrating immune cells. Importantly, MDOTS/PDOTS
are not to be confused with organoids, a distinct 3D culture
method developed by Hans Clevers and Toshiro Sato, which
leverages native tissue stem cells to propagate normal or
transformed tissue.25 Organoids, like PDXs and CTCs, can be
used as part of personalized medicine efforts, but lack native
stromal and immune cells, thus precluding study of tumor–
immune interactions. Furthermore, generation of sufficient
quantity of organoids takes time, thus limiting rapid drug
screening capabilities.
MDOTS/PDOTS offer significant advantages over
organoids, PDXs, and CTCs for ex vivo profiling tumor–im-
mune responses to ICB, however there are several impor-
tant limitations inherent in the current version of the
platform. First, the current version of the MDOTS/PDOTS
platform is currently only capable of evaluating tumor–im-
mune interactions of immune cells that have already infil-
trated the tumor. In other words, PDOTS/MDOTS “v1.0”
cannot recapitulate T-cell priming (which occurs primarily
in lymph nodes) or recruitment of naïve immune cells to
the tumor microenvironment. Second, we have yet to per-
form comprehensive evaluation of tumor, stromal, and im-
mune changes through the course of ex vivo culture, both
in control conditions and in response to ICB. Thirdly, use
of core needle biopsies and FNAs is challenging, and exci-
sional specimens are preferred to yield sufficient number
& quality of MDOTS/PDOTS for ex vivo profiling at pres-
ent, lastly, the influence of device dimensions, biophysical
parameters, interstitial flow, hypoxia, and metabolic on tu-
mor–immune interactions, especially cytokine production
remains poorly understood and will require further
investigation.
It should be noted that the size of the gel region and the
size of the media channels are among the variables that may
differ among different versions and types of microfluidic de-
vices that could conceivably influence absolute and relative
cytokine changes. The impact of different device parameters
(e.g. device height, gel region width) on cytokine elaboration
is under investigation, but remains far from complete. Identi-
fying the physical components & dimensions of the micro-
fluidic device that enables studying ICB will be important, es-
pecially when considering building more advanced medium-
and high-throughput systems to test multiple drugs and/or
antibodies in combination. An important co-variate in this
analysis is the composition of the device itself. For example,
the AIM microdevice is plastic, whereas other materials (e.g.
polydimethylsiloxane, PDMS) used for ‘home grown’ device
fabrication exhibit different properties and characteristics.
This is a particularly important consideration when testing
ICB in combination with small molecules (commonly pre-
pared in DMSO), as PDMS is known to adsorb small hydro-
phobic molecules,26 likely influencing drug delivery to
MDOTS/PDOTS and ultimately drug efficacy.
While the long-term potential of MDOTS/PDOTS tech-
nology as a predictive tool is not yet clear, MDOTS/PDOTS
are showing great promise in the evaluation of novel com-
bination therapies and in the discovery of novel bio-
markers. Important future directions include extending the
lifetime of ex vivo cultures (e.g. tumor vascular networks),
performing clinical validation studies (e.g. co-clinical trials
or adaptive clinical trials using ex vivo responses to guide
clinical treatment), and developing medium- and high-
throughput versions of the system. With further technol-
ogy development along with improved data analytics and
bioinformatics, we anticipate the MDOTS/PDOTS platform
will form the foundation of functional precision immune-
oncology efforts.
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